Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK4 | O00444 | 2/20 | 0.40 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.40 |
| ▸ | JAK2 | O60674 | 2/20 | 0.40 |
| ▸ | CDK1 | P06493 | 2/20 | 0.40 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.40 |
| ▸ | CDK2 | P24941 | 2/20 | 0.40 |
| ▸ | TYK2 | P29597 | 2/20 | 0.40 |
| ▸ | CLK2 | P49760 | 2/20 | 0.40 |
| ▸ | JAK3 | P52333 | 2/20 | 0.40 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.40 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.40 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.40 |
| ▸ | PKN2 | Q16513 | 2/20 | 0.40 |
| ▸ | HIPK4 | Q8NE63 | 2/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.40 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.40 |
| ▸ | AKT3 | Q9Y243 | 2/20 | 0.40 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10097376 | 0.95 | AR (0.41) | PLK4DAPK3JAK2CDK1RPS6KB1 | |
| SCHEMBL10252757 | 0.93 | PLK4 (0.37) | PLK4DAPK3JAK2CDK1RPS6KB1 | |
| SCHEMBL10249433 | 0.92 | SGK1 (0.36) | PLK4DAPK3JAK2CDK1RPS6KB1 | |
| SCHEMBL10252484 | 0.91 | PLK4 (0.40) | PLK4DAPK3JAK2CDK1RPS6KB1 | |
| SCHEMBL10249405 | 0.90 | NPC1 (0.42) | PLK4DAPK3JAK2CDK1CDK2 | |
| SCHEMBL13152362 | 0.88 | GRIK2 (0.43) | PLK4DAPK3JAK2CDK1RPS6KB1 | |
| SCHEMBL13151765 | 0.87 | BRD4 (0.35) | PGRRIPK2ACVR1NOD2NPC1 | |
| SCHEMBL10095722 | 0.86 | PGR (0.41) | PLK4DAPK3JAK2CDK1RPS6KB1 | |
| SCHEMBL13151753 | 0.86 | KIF11 (0.41) | PLK4DAPK3JAK2CDK1RPS6KB1 | |
| SCHEMBL13152374 | 0.86 | PLK4 (0.40) | PLK4DAPK3JAK2CDK1RPS6KB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| WO-2010118009-A1 | HCV INHIBITOR AND THERAPEUTIC AGENT COMBINATIONS | PTC THERAPEUTICS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | OAT, HAVCR2, HCCS | PLK4 4295/4885DAPK3 3484/4885JAK2 2860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.